Development of D-box peptides to inhibit the anaphase-promoting complex/cyclosome
E3 ubiquitin ligases engage their substrates via ‘degrons’ - short linear motifs typically located within intrinsically disordered regions of substrates. As these enzymes are large, multi-subunit complexes that generally lack natural small-molecule ligands and are difficult to inhibit via conventional means, alternative strategies are needed to target them in diseases, and peptide-based inhibitors derived from degrons represent a promising approach. Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase-promoting complex/cyclosome (APC/C) that is essential in mitosis and consequently of interest as an anti-cancer target. APC/C engages substrates via degrons that include the ‘destruction box’ (D-box) motif. We used a rational design approach to construct binders containing unnatural amino acids aimed at better filling a hydrophobic pocket that contributes to the D-box binding site on the surface of Cdc20. We confirmed binding by thermal-shift assays and surface plasmon resonance and determined the structures of a number of the Cdc20-peptide complexes. Using a cellular thermal shift assay, we confirmed that the D-box peptides also bind to and stabilise Cdc20 in the cell. We found that the D-box peptides inhibit ubiquitination activity of APC/C Cdc20 and are more potent than the small-molecule inhibitor Apcin. Lastly, these peptides function as portable degrons capable of driving the degradation of a fused fluorescent protein. Interestingly, we find that although inhibitory activity of the peptides correlates with Cdc20-binding affinity, degradation efficacy does not, which may be due to the complex nature of APC/C regulation and effects of degron binding of subunit recruitment and conformational changes. Our study lays the groundwork for the further development of these peptides as molecular therapeutics for blocking APC/C as well as potentially for harnessing the APC/C for targeted protein degradation.
Authors
- Maria Zacharopoulou (ORCID: https://orcid.org/0000-0002-3660-2797)
- Marianne Schimpl (ORCID: https://orcid.org/0000-0003-2284-5250)
- Elda Fisher (ORCID: https://orcid.org/0000-0001-9795-5839)
- Cynthia Okoye (ORCID: https://orcid.org/0000-0002-0406-3733)
- Christopher Phillips (ORCID: https://orcid.org/0000-0002-9601-0128)
- Thomas Tischer (ORCID: https://orcid.org/0000-0002-6845-2762)
- Rohan Eapen (ORCID: https://orcid.org/0000-0001-7269-3633)
- Laura S. Itzhaki (ORCID: https://orcid.org/0000-0001-6504-2576)
- Catherine Lindon (ORCID: https://orcid.org/0000-0003-3554-2574)
- David R. Spring (ORCID: https://orcid.org/0000-0001-7355-2824)
- Christopher J. Stubbs (ORCID: https://orcid.org/0000-0002-2373-5478)
- David Barford (ORCID: https://orcid.org/0000-0001-8810-950X)
- Fernando Ferrer
Institutions
- MRC Laboratory of Molecular Biology (GB)
- University of Cambridge (GB)
- AstraZeneca (Brazil) (BR)
Publication Details
- Journal
- eLife
- Published
- 2025-09-01
- DOI
- https://doi.org/10.7554/elife.104238.3
- Primary Topic
- Microtubule and mitosis dynamics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Research UK
- Rosetrees Trust
- Gates Cambridge Trust
- Biotechnology and Biological Sciences Research Council